| 6.82 Real-Time Quote |  -0.10 / -1.45%Today’s Change | 6.34 Today|||52-Week Range 15.96 | -15.70% Year-to-Date |
| Biotech Stock Mailbag: Amarin, MannKind, Palatin 7:08am / TheStreet.com | 2013 FDA Drug Approval Calendar May 21 / TheStreet.com |
| Why Keryx is Lagging But Acadia is Zooming (Hint: It's About NCE) May 21 / TheStreet.com |
| Previous close | 6.92 |
| Today’s open | 6.84 |
| Day’s range | 6.74 - 6.90 |
| Volume | 1,476,153 |
| Average volume (3 months) | 3,666,074 |
| Market cap | $1.0B |
| Dividend yield | -- |
| Earnings growth (last year) | -133.73% |
| Earnings growth (this year) | -56.14% |
| Earnings growth (next 5 years) | +30.70% |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | -- |
| Today’s change | Today’s % change | |
|---|---|---|
| NKTRNektar Therapeutics | -0.04 | -0.38% |
| LXRXLexicon Pharmaceutic... | -0.04 | -2.05% |
| EXELExelixis Inc | -0.02 | -0.42% |
| BRLIBio-Reference Labora... | -0.48 | -1.54% |
| Next reporting date | August 13, 2013 |
| EPS forecast (this quarter) | -$0.38 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$179.5M |
| Net profit margin | -- |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Executive Chairman & Chief Executive Officer Joseph S. Zakrzewski, MBA |
President & Chief Financial Officer John F. Thero, CPA |
Corporate headquarters Dublin, Dublin |
.
